Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapy - Wikidata - wikimedia - TriplyDB

Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapy

Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapy

http://www.wikidata.org/entity/Q24679781

about

Retargeting Strategies for Oncolytic Herpes Simplex Viruses Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival.Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma.HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study.Experimental approaches for the treatment of malignant gliomas.Oncolytic viral therapies.Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.Hypoxia Moderates γ(1)34.5-Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary Cultures.Oncolytic viruses in the treatment of bladder cancer Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas.Gene therapy for gastric cancer: is it promising?Herpes simplex virus 1 (HSV-1) for cancer treatment.Gene therapeutics: the future of brain tumor therapy?The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, MyD116, and GADD34.An acutely and latently expressed herpes simplex virus 2 viral microRNA inhibits expression of ICP34.5, a viral neurovirulence factor.Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors.Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs Advances in oncolytic virus therapy for glioma.Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways.Glioma virus therapies between bench and bedside.Clinical development directions in oncolytic viral therapy.Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines.Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer--expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy.Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence.Treatment of solid sarcomas in immunocompetent mice with novel, oncolytic herpes simplex viruses.Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): relevance for gene and cancer therapy.Variability in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors.HSV1716 persistence in primary human glioma cells in vitro.Review: Oncolytic virotherapy, updates and future directions.Proliferative activity and in vitro replication of HSV1716 in human metastatic brain tumours.Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles.RESTRICTION OF γ34.5-DELETED ONCOLYTIC HERPES SIMPLEX VIRUS REPLICATION IN GLIOBLASTOMA STEM-LIKE CELLS.

P2860

Q26765439-13C7C7AB-06B0-4663-9F5E-1B64E22344AE Q26998111-82D2380D-E3F8-473E-967F-C9766DF7367A Q27007519-835CBC05-9AA1-49D5-9CAB-A0C858CDB430 Q30954768-6199E692-9AB1-4ECA-9CE3-9BB3F9E74EC1 Q33566511-0EB15038-32CE-4A3B-B810-3FEE4EECD95E Q33725706-0F70354E-FAF0-47EE-A764-F4A2FF5E07D7 Q33905047-15C120F3-7116-4C37-A55C-27129A69D8D6 Q33995752-3B43439A-E8AF-42E2-BC74-6B6EDACFB392 Q34124333-8788310A-FF52-4EC7-96CE-AE7382A5E1DA Q34127138-6E7BD310-5C07-42F3-A641-8B56AB8B280E Q35852258-923CD04C-F5DA-452B-9ACC-A1BE4CD700EF Q35867997-DAD3E5FA-30E1-4BCD-BC50-63D19D7AAD99 Q35945465-496C2EA9-E5F8-4A65-ACB1-1BB7348C1E1D Q36061803-C36B7D82-B04F-49F0-BF50-805C0D3C12B6 Q36147934-99682F7E-633F-476A-8268-566C594D545B Q36367428-90BDC376-1703-449F-9B88-9FF4BEFA8D7B Q36401504-155B85F6-D38B-4946-AD53-D7F0A7EF976B Q36444443-DF3056A2-BD0B-446C-952D-B7B06F52AFA0 Q36532106-EE89B746-A4AC-48ED-ABDA-566714647984 Q36548927-DC60C8A7-3E29-471D-ABC9-2341FF581FEF Q36825232-DC60D6DF-1EF6-4D6D-AD56-AAE972BA3AF2 Q36849213-F0469AA5-F6BB-4A81-9D52-D7F7F26514DC Q37031896-4A727154-AB7D-430B-8D71-6DC68A5A68E7 Q37287118-F34474C6-55C7-4E1A-892E-5D2ADC738BB8 Q37564490-2A1C7B00-F063-41DC-92C5-199723CA644F Q37580510-5797154A-81E7-4B48-91D4-D6F38D10A389 Q37857659-B696628C-FE3B-4D55-9D0E-110DBAA4AB97 Q37899230-45594296-E739-4DA6-82E6-7B7903D501AE Q38781322-7F6FA243-271B-41C6-AB33-3BA7875CF650 Q40104793-7A2DF89D-8EC2-4C21-A2DB-EE6B12F4C646 Q40235064-9AB8D435-6DD3-42FD-B651-BF6D66265CEB Q40373406-13BF82C1-C015-476E-BEB0-A8A6DD114B1D Q40564263-857DAF99-346E-4940-8D0A-61A51E4707F8 Q45752750-40E46DCA-9933-4255-91FB-D59622AEF236 Q45880904-FF346DD8-8090-4D91-8154-63CB39B21FED Q45888466-640975B3-16E1-4B66-92C6-9E4D20AC97CA Q47160989-F3A71FAA-A71C-4621-9A55-320DA9D1263D Q48235538-5529D275-9991-4008-8F59-8F656F017F17 Q53681637-07ACEA4C-5318-4392-87F5-34144C2089DF Q55456991-11150702-0DB9-4B72-BB06-F95163826E06

P2860

Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapy

http://www.wikidata.org/entity/Q24679781

description

1996 nî lūn-bûn

@nan

1996 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

1996 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

name

Selective in vitro replication ...... lly effective clinical therapy

@ast

Selective in vitro replication ...... lly effective clinical therapy

@en

Selective in vitro replication ...... lly effective clinical therapy

@nl

type

label

Selective in vitro replication ...... lly effective clinical therapy

@ast

Selective in vitro replication ...... lly effective clinical therapy

@en

Selective in vitro replication ...... lly effective clinical therapy

@nl

prefLabel

Selective in vitro replication ...... lly effective clinical therapy

@ast

Selective in vitro replication ...... lly effective clinical therapy

@en

Selective in vitro replication ...... lly effective clinical therapy

@nl

P1433

Q24679781-EDE156C7-1D73-485A-85DD-03FEB33B8D93

P1476

Q24679781-023939BA-0833-4B3B-A8C6-3492D1A300C1

P2093

Q24679781-00A0B502-C77B-4AA9-AF38-3D75A5F95A11

Q24679781-1D7DFDC3-95D5-4939-9D7B-29CD9DB2E8D9

Q24679781-641B727E-BBB6-4931-8A92-757E49E88E5C

Q24679781-70371B8F-E4C0-4E77-9E2D-2BCFCD24DD1A

Q24679781-8EE86D79-6B7D-45A0-A133-045D67BF3B66

Q24679781-DCF4A386-E8E1-4B33-8FF8-01F101F9463D

Q24679781-F6D19888-7CF6-4402-B61E-62074FDA8F3B

Q24679781-FDC788F6-C07C-4E68-9C30-E15CC96C5A1A

P2860

Q24679781-06899DAE-B5B0-436E-96B7-5E2246666353

Q24679781-08DFEB03-7DFE-49C3-8045-ADA4C137B12E

Q24679781-22B50D03-7DB0-43BE-9F0E-92555E07DF2D

Q24679781-2969B212-D3B6-42A2-97B5-0B2BE0FC4DB5

Q24679781-2BBC0837-C7C4-48EC-814B-7276689859D7

Q24679781-33134B39-8146-459B-9515-9D6AED79F66B

Q24679781-34A2C398-B20F-4CFC-8F31-10AFA633DE7E

Q24679781-46BECCB5-94E8-4B7C-B4A0-9564B53DB0FE

Q24679781-46CD773C-463A-413C-9C64-166E1536DF76

Q24679781-48CE416D-B16A-44DD-954C-531178377DF3

P2888

Q24679781-71F40B46-235D-4E1C-80D7-3EF56C481167

P304

Q24679781-D512AFCF-849C-4D7A-B1AB-3F40A74B7515

P31

Q24679781-6C3DE74D-A24D-432B-802C-2C5071EE5AE8

P356

Q24679781-E1E96C33-4F45-4213-8992-82AC747FBC70

P407

Q24679781-3A9AD58D-D6DC-4BF8-AD2C-1926F53382E9

P433

Q24679781-54D15724-EE7E-43D4-BBFC-ABD9106BA052

P478

Q24679781-D661533F-CC17-440A-83BB-65DA24AECCDB

P577

Q24679781-6D052D75-9377-4648-8C18-30C615E2B4A3

P5875

Q24679781-358B8FE7-437A-4C5B-B891-D4614068B1F2

P6179

Q24679781-F65226E5-C381-448D-81C9-2181A891457E

P698

Q24679781-FF5CC6C9-DFEB-456C-9946-49CA631CAB32

P921

Q24679781-88C83470-C513-44EE-94BC-A7ABD5B47C33

P932

Q24679781-67F7934C-449A-4905-B8C0-CC4395613E98

P356

P1433

British Journal of Cancer

P1476

Selective in vitro replication ...... lly effective clinical therapy

@en

P2093

A D Lewis

http://www.w3.org/2001/XMLSchema#string

A R MacLean

http://www.w3.org/2001/XMLSchema#string

E A McKie

http://www.w3.org/2001/XMLSchema#string

G Cruickshank

http://www.w3.org/2001/XMLSchema#string

P G Kennedy

http://www.w3.org/2001/XMLSchema#string

R Rampling

http://www.w3.org/2001/XMLSchema#string

S C Barnett

http://www.w3.org/2001/XMLSchema#string

S M Brown

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study.

Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate.

Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant.

Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas.

Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2.

Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma.

Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence.

The terminal a sequence of the herpes simplex virus genome contains the promoter of a gene located in the repeat sequences of the L component.

The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells.

Growth of a rat neuroblastoma cell line in serum-free supplemented medium.

P2888

P304

745-52

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.1996.431

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P577

1996-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14406849

http://www.w3.org/2001/XMLSchema#string

P6179

1022391280

http://www.w3.org/2001/XMLSchema#string

P698

8795577

http://www.w3.org/2001/XMLSchema#string

P921

P932

2074706

http://www.w3.org/2001/XMLSchema#string